{ "ok": true, "cik": "1588978", "ticker": "PRCT", "name": "PROCEPT BioRobotics Corporation", "filings": [ { "form": "8-K", "filed": "2026-09-24", "items": [ "1.01 Entry into a Material Definitive Agreement", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1588978/000158897826000034/0001588978-26-000034-index.htm" }, { "form": "10-Q", "filed": "2026-08-05", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1588978/000158897826000030/0001588978-26-000030-index.htm" }, { "form": "8-K", "filed": "2026-08-04", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1588978/000158897826000028/0001588978-26-000028-index.htm" }, { "form": "8-K", "filed": "2026-06-10", "items": [ "5.07 Submission of Matters to a Vote of Security Holders" ], "url": "https://www.sec.gov/Archives/edgar/data/1588978/000158897826000026/0001588978-26-000026-index.htm" }, { "form": "10-Q", "filed": "2026-04-30", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1588978/000158897826000022/0001588978-26-000022-index.htm" }, { "form": "8-K", "filed": "2026-04-29", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1588978/000158897826000020/0001588978-26-000020-index.htm" } ], "events12m": 8, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001588978.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1588978" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets and no trading recommendations.", "edgar": "🫧 Edgar looked up PROCEPT BioRobotics Corporation ($PRCT). Last filing: 8-K (1.01 Entry into a Material Definitive Agreement), 2026-09-24. 8 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 308054000, "revenueGrowth1y": 0.3721903981327228, "revenueGrowthPerYear": 0.728967951783456, "yearsOfData": 5, "operatingMargin": -0.3371454355405221, "operatingMarginPrior": -0.4303557269997951, "netMargin": -0.3102443078161621, "operatingCashFlow": -48985000, "capitalSpending": 9356000, "freeCashFlow": -58341000, "researchAndDevelopment": 71277000, "researchShareOfRevenue": 0.23137826484966922, "cash": 286503000, "longTermDebt": 51615000, "longTermDebtChange": 0.002778209511967722, "revenueHistory": [ { "fiscalYearEnd": "2021-12-31", "revenue": 34473000 }, { "fiscalYearEnd": "2022-12-31", "revenue": 75014000 }, { "fiscalYearEnd": "2023-12-31", "revenue": 136191000 }, { "fiscalYearEnd": "2024-12-31", "revenue": 224498000 }, { "fiscalYearEnd": "2025-12-31", "revenue": 308054000 } ], "totalEquity": 365870000, "totalAssets": 508081000, "equityRatio": 0.7201017160649581, "returnOnEquity": -0.2612184655752043, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "earningsPerShare": -1.72, "sharesOutstanding": 55544000, "bookValuePerShare": 6.58703010226127, "revenuePerShare": 5.546125594123578, "range80": { "low": 349498261.6573228, "high": 578952904.7968551, "baseline": 458010379.05383706, "n": 4309, "band": "b01", "bandLabel": "$100M–1B", "method": "v4.1", "credibility": 0.5, "growthYears": 4, "ownVolatility": 0.1923249844153526, "classVolatility": 0.1022985825903761, "volatility": 0.15403554724537713 }, "ifPaceHeld": { "low": 349498261.6573228, "high": 578952904.7968551 } }, "edgarette": "🔖 Exposure: revenue $308.1M (FY2025), total debt $51.6M. Experience: revenue up 37.2% on the year, up 72.9% a year over 4 years; operating margin -33.7%, up from -43.0%. Soundness: equity 72.0% of assets, return on equity -26.1%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $349.5M and $579.0M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; on a year the method never saw, 83.4% landed inside). In a shock year the stress range is $307.6M to $661.2M. A range, not a forecast. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -33.7% against a 1.2% median; growth 37.2% against 11.6%.", "peers": { "sic": 3841, "sicDescription": "Surgical & Medical Instruments & Apparatus", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "3841", "growth": [ 0.1161, 60 ], "opMargin": [ 0.0124, 60 ], "equityRatio": [ 0.5291, 59 ], "returnOnEquity": [ -0.0233, 55 ], "payoutRatio": [ 0.3812, 8 ] }, "summary": "PROCEPT BioRobotics (PRCT) grew revenue 37.2% in FY2025 to $308 million, operating margin -33.7% against a 1.2% median for surgical & medical instruments & apparatus, equity 72.0% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
PROCEPT BioRobotics Corporation against its own record and its peers
Operating marginPeer median 1.2%-33.7%Revenue, on the yearPeer median 11.6%37.2%Equity of assetsPeer median 52.9%72.0%Return on equityPeer median -2.3%-26.1%Gold tick: the median of 55–59 peers with $50M+ revenue in surgical & medical instruments & apparatus
", "chartHorizon": null, "backtest": { "tests": 2, "hits": 0, "rate": 0, "method": "v4", "byYear": { "2024": [ 0, 1 ], "2025": [ 0, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-09-25T14:01:01.913Z", "hash": "432b338747969671", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "PROCEPT BioRobotics (PRCT) grew revenue 37.2% in FY2025 to $308 million, operating margin -33.7% against a 1.2% median for surgical & medical instruments & apparatus, equity 72.0% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 308054000, "totalDebt": 51615000, "cash": 286503000 }, "experience": { "revenueGrowth1y": 0.3721903981327228, "revenueGrowthPerYear": 0.728967951783456, "operatingMargin": -0.3371454355405221, "operatingMarginPrior": -0.4303557269997951, "netMargin": -0.3102443078161621, "freeCashFlow": -58341000 }, "soundness": { "equityRatio": 0.7201017160649581, "returnOnEquity": -0.2612184655752043, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 3841, "sicDescription": "Surgical & Medical Instruments & Apparatus", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "3841", "growth": [ 0.1161, 60 ], "opMargin": [ 0.0124, 60 ], "equityRatio": [ 0.5291, 59 ], "returnOnEquity": [ -0.0233, 55 ], "payoutRatio": [ 0.3812, 8 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "range": { "low": 349498261.6573228, "high": 578952904.7968551, "baseline": 458010379.05383706, "coverage": 0.8, "method": "v4.1", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); width = the company's own volatility of yearly growth, credibility-weighted against its size class (Buhlmann), scaled to the 80% target on 2023 and tested on 2024", "calibratedOn": { "companyYears": 4309, "sizeBand": "$100M–1B", "fitYears": [ 2018, 2022 ], "tuneYear": 2023, "testYear": 2024, "coverageOnTestYear": 0.8341 }, "credibility": { "weightOnOwnRecord": 0.5, "growthYears": 4, "ownVolatility": 0.1923249844153526, "classVolatility": 0.1022985825903761, "pricedVolatility": 0.15403554724537713, "k": 3 }, "stress": { "low": 307603539.74442154, "high": 661186701.2829306, "basis": "the same range with widths set to hold 80% across 2018-2023, pandemic years included" }, "kind": "a statistical range, not company guidance; no view on the share price", "track": { "backtest": { "tests": 2, "hits": 0, "rate": 0, "method": "v4", "byYear": { "2024": [ 0, 1 ], "2025": [ 0, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-09-25T14:01:01.913Z", "hash": "432b338747969671", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001588978.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1588978" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }